Learn more about whether Alvotech or Merus N.V. is a better investment based on AAII's A+ Investor grades, which compare both ...

Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.

Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...

Olezarsen目前正在接受欧洲药品管理局对FCS治疗的审查，预计将在今年内获得批准。Sobi在超过30个国家拥有商业存在，将负责在其区域内的监管提交和商业化，并借助其在Waylivra®（欧洲唯一获批的FCS药物）方面的经验。Ionis将从Sobi获得预付款、基于里程碑的付款，以及高达20%中段的年度净销售额分级特许权使用费。

Below, check out the roundup of California Healthline’s coverage. For today's national health news, read KFF Health News’ Morning Briefing.

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...